Market Research Report
Asia Pacific Biodefense Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Anthrax, Small pox, Botulism, Radiation/Nuclear, Others), and Geography
|Published by||The Insight Partners||Product code||936591|
|Published||Content info||100 Pages
Delivery time: 1-2 business days
|Asia Pacific Biodefense Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Anthrax, Small pox, Botulism, Radiation/Nuclear, Others), and Geography|
|Published: April 29, 2020||Content info: 100 Pages||
Asia Pacific, the Biodefense Market, is anticipated to reach US$ 1,520.67 Mn in 2027 from US$ 723.70 Mn in 2019. The market is projected to grow with a CAGR of 9.8% from 2020-2027.
The Biodefense Market is growing primarily due to the presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. Restraining factors, such as low R&D funding by government in developing and underdeveloped economies likely to damage the growth of the market in the coming years. Additionally, increased adoption of technologies and predictive analytics to reshape biodefense market are likely to increase the growth of the biopharmaceuticals contract manufacturing in the forecast period.
Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.
Every year, the government is spending heavily on the R&D of vaccines to stay prepared for any bioterrorism attacks. For instance, in Japan reinforcing public health biopreparedness and preventive measures (pathogen control) were followed by enhancement of R&D and networking for biosecurity as a key agenda under "Safe and Secure Society" initiative. Pandemic preparedness was significantly improved after 2009 with the Special Measures Act for crisis management. More recently, the National Institute of Allergy and Infectious Diseases (NIAID) Office of Biodefense Research and Surety has been engaged with Japan in medical research issues involved with biosecurity and biodefense under the U.S. - Japan Framework Initiative for a Safe and Secure Society. As the government engages in these current and future policy activities, understanding the existing biosecurity and biodefense policy, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for any bioterrorism. The initiatives of governments open a window of opportunities for the firms involved in the biodefense sector.
Moreover, due to factors such as increasing border threats, rising national security concerns, and changing dynamics of warfare, countries such as China, Japan, India in Asia Pacific are inclined towards enhancing their missile weapon store. They are also modernizing their old missiles with the new propulsion system and warheads. Hence, as the threat for biological weapon and nuclear armed ICBM is increasing, governments of various countries are actively funding for biodefense, thereby, positively propelling the Asia Pacific market. Thus, owing to the factors mentioned above are likely to boost the growth of the Biodefense Market in Asia Pacific during the forecast period.
In 2019, the anthrax segment accounted for the largest market share in the Biodefense Market in Asia Pacific. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives in Asian countries, such as safe and security initiative , Special Measures Act for Pandemic preparedness, Civilian Protection Act and the Defense Research and Development Establishment (DRDE).
Some of the significant secondary sources for cold plasma equipment included in the report are the World Health Organization (WHO) and the Food and Drug Administration (FDA).